CoChat

The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects

James, A. P., Watts, G. F., Mamo, J. C. L. · 2005 · Diabetes, Obesity and Metabolism
Cited by 40

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Introduction: Obese insulin‐resistant individuals exhibit a dyslipidaemia due to raised levels of both hepatically and intestinally derived lipoproteins. However, little is known about the related dysregulation of intestinally derived lipoproteins. We examined whether the insulin‐sensitizing agents, metformin and rosiglitazone, improve intestinal lipoprotein metabolism in obese insulin‐resistant individuals. Methods: Thirty male obese (body mass index > 26; waist circumference > 100 cm) insulin‐resistant [homeostasis model assessment (HOMA) score > 2.0] subjects were randomized to either a metformin (1 g bd), rosiglitazone (4 mg bd) or control treatment group for a period of 8 weeks. Fasting and postprandial lipid metabolism was studied before and after the intervention period. Results: Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia. With rosiglitazone relative to control there was a significant (p < 0.05) increase in the area under the apolipoprotein (apo) B48 curve following the oral fat load and a decrease in the ratio of triglyceride to apo B48 levels postprandially following rosiglitazone treatment. Conclusion: In obese insulin‐resistant subjects metformin and rosiglitazone both improve insulin sensitivity, as measured by HOMA, without improvement in lipid metabolism. Rosiglitazone may have a detrimental effect on chylomicron metabolism by an increase in postprandial apo B48 levels, and this requires further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00407.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 40

Metadata

Authors
James, A. P., Watts, G. F., & Mamo, J. C. L.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2004-11-24
Volume
7
Issue
4
Pages
381-389
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2021842632
Cited by
40
References
10
FWCI
1.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00407.x
The paper
James, A. P., Watts, G. F., & Mamo, J. C. L. (2005). The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00407.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.